摘要
目的探究鲑降钙素对维持性血液透析(MHD)合并骨质疏松患者骨密度及骨代谢指标的影响。方法选取2020年1月-2023年6月于我院就诊的MHD合并骨质疏松患者60例,按随机数字表法将其分为研究组和照组,每组各30例。对照组口服骨化三醇软胶囊,研究组在上述基础上于透析结束后经皮下注射鲑降钙素注射液,两组均治疗6个月。对比两组临床疗效、骨密度指标、骨代谢及骨转换指标、疼痛程度。结果研究组治疗总有效率为80.00%,高于对照组的53.33%,具有统计学差异(P<0.05)。相比于对照组,研究组治疗后骨密度值较高,骨吸收标志物β胶联降解产物(β-CTX)、血清骨钙素(OC)、Ⅰ型前胶原氨基末端前肽(PⅠNP)水平、碱性磷酸酶(ALP)、25-羟维生素D25(OH)D及甲状旁腺素(PTH)水平均较低,具有统计学差异(P<0.05)。相比于对照组,研究组治疗后VAS评分较低,具有统计学差异(P<0.05)。研究组不良反应发生率为6.67%,低于对照组的26.67%,具有统计学差异(P<0.05)。结论鲑降钙素在MHD合并骨质疏松患者治疗中效果较好,能够有效提升骨密度值,改善骨代谢及骨转换指标,并可减轻疼痛感,且不良反应较少,安全性高,值得推广应用。
Objective:To explore the effect of salmon calcitonin on bone mineral density and bone metabolism indexes in patients with maintenance hemodialysis(MHD)complicated with osteoporosis.Methods:A total of 60 MHD patients with osteoporosis treated in our hospital from January 2020 to June 2023 were selected,and were divided into the study group and the control group according to the random number table method,with 30 cases in each group.The control group was treated with calcitriol soft capsules orally,and the study group was subcutaneously treated with salmon calcitonin injection after dialysis on the basis of the above.Both groups were treated for 6 months.The clinical efficacy,bone mineral density,bone metabolism,bone turnover and pain degree between the two groups were compared.Results:The total effective rate of the study group was 80.00%,which was higher than 53.33%of the control group,with statistical differences(P<0.05).Compared with the control group,bone mineral density values were higher in the study group after treatment,and bone resorption markersβglued degradation products(β-CTX),serum osteocalcin(OC),type I procollagen amino terminal propeptide(PⅠNP),alkaline phosphatase(ALP)25 hydroxyvitamin D25(OH)D and the levels of parathyroid hormone(PTH)were lower,with statistical differences(P<0.05).Compared with the control group,the VAS score of the study group was lower after treatment,with statistical differences(P<0.05).The incidence of adverse reactions in the study group was 6.67%,which was lower than 26.67%in the control group,with statistical differences(P<0.05).Conclusion:Salmon calcitonin has a good effect in the treatment of MHD patients with osteoporosis,which can effectively increase bone mineral density,improve bone metabolism and bone turnover indexes,and reduce pain,with less adverse reactions and high safety,worthy of promotion and application.
作者
谢丽慧
郭彦龙
杨正生
XIE Li-hui;GUO Yan-long;YANG Zheng-sheng(People's Hospital of Ganxian District,Ganzhou Jiangxi 341100,China)
出处
《透析与人工器官》
2024年第4期62-65,共4页
Chinese Journal of Dialysis and Artificial Organs
关键词
维持性血液透析
骨质疏松
鲑降钙素
骨化三醇
骨密度
骨代谢指标
maintenance hemodialysis
osteoporosis
salmon calcitonin
calcitriol
bone mineral density
bone metabolism index
